Trovera buys Thyrocare's radiology arm for $150M as diagnostics firm doubles down on pathology
What's the deal? India's Thyrocare TechnologiesDealroom has a profile for this one. Try Dealroom → is selling its entire stake in radiology subsidiary Nueclear HealthcareDealroom has a profile for this one. Try Dealroom → to Trovera HealthcareDealroom has a profile for this one. Try Dealroom → for roughly US$192M. The board approved the sale of 1,11,11,000 shares — 100% of Nueclear's equity — on September 21, 2026.
How it's structured. The consideration mixes cash and equity: Thyrocare will take 42,500 compulsorily convertible preference shares (CCPS) in Trovera valued at US$8.08M, plus about US$11.1M in cash. Each CCPS carries a face value of US$0.14, issued at a US$190 premium.
Why now? Thyrocare cited the radiology unit's ongoing need for investment in equipment, technology, and infrastructure. Exiting lets it concentrate capital and management on its core pathology business.
What changes. Once complete, Nueclear will no longer be a Thyrocare subsidiary. Thyrocare will separately buy the land and buildings Nueclear operates in Gurugram and Hyderabad for US$2.8M, keeping ownership of those premises.
The valuation was set by V. B. Desai Financial ServicesDealroom has a profile for this one. Try Dealroom →. The deal needs shareholder and regulatory approval, with completion expected by November 30, 2026.
The signal: The move sharpens the line between diagnostic imaging and lab testing in India's health services market, with Thyrocare betting that a focused pathology play beats a capital-hungry radiology footprint.
Read more: investywise.com
Image credit: U.S. Department of Agriculture
